A coronavirus vaccine being developed by the University of Oxford and AstraZeneca is safe and shows signs of inducing an immune response, according to early clinical trial results published Monday in the medical journal The Lancet.
The trial did not look at whether the vaccine prevents coronavirus infection, however. That’s a question that will be answered in trials that are currently ongoing.
The trial results found that it generated two “strong” immune responses: the production of both antibodies and T cells, which find and attack virus cells.
“We’re getting both sides of the immune system stimulated and that is fairly unusual for vaccines,” Adrian Hill, director of the Jenner Institute at Oxford University, told NBC News.
It is “good news — another step forward on the long road” to having a COVID-19 vaccine,” said Dr. William Schaffner, an infectious disease expert at Vanderbilt University Medical Center in Nashville. Schaffner was not involved in the vaccine research.